142 related articles for article (PubMed ID: 38451196)
21. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
22. Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial.
Fosbøl MØ; Kurbegovic S; Johannesen HH; Røder MA; Hansen AE; Mortensen J; Loft A; Petersen PM; Madsen J; Brasso K; Kjaer A
J Nucl Med; 2021 Mar; 62(3):354-359. PubMed ID: 32764119
[TBL] [Abstract][Full Text] [Related]
23. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.
Christensen A; Juhl K; Persson M; Charabi BW; Mortensen J; Kiss K; Lelkaitis G; Rubek N; von Buchwald C; Kjær A
Oncotarget; 2017 Feb; 8(9):15407-15419. PubMed ID: 28039488
[TBL] [Abstract][Full Text] [Related]
24. Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.
Leth JM; Newcombe EA; Grønnemose AL; Jørgensen JT; Qvist K; Clausen AS; Knudsen LBS; Kjaer A; Kragelund BB; Jørgensen TJD; Ploug M
Sci Rep; 2023 Oct; 13(1):17248. PubMed ID: 37821532
[TBL] [Abstract][Full Text] [Related]
25. A novel urokinase plasminogen activator receptor-targeted peptide-based probe for in-vivo molecular imaging of glioblastoma.
Han Y; Tu L; Zhang Y; Xu L; Sun Z
Nucl Med Commun; 2023 Feb; 44(2):142-149. PubMed ID: 36630218
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients.
Risør LM; Binderup T; Fosbøl MØ; Andersen KF; Loft A; Friborg J; Kjaer A
Sci Rep; 2022 Nov; 12(1):19126. PubMed ID: 36352036
[TBL] [Abstract][Full Text] [Related]
27.
Vats K; Sharma R; Sarma HD; Satpati D; Dash A
Anticancer Agents Med Chem; 2018; 18(9):1289-1294. PubMed ID: 29546835
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.
Persson M; Kjaer A
Clin Physiol Funct Imaging; 2013 Sep; 33(5):329-37. PubMed ID: 23701192
[TBL] [Abstract][Full Text] [Related]
29. uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study.
Fosbøl MØ; Mortensen J; Petersen PM; Loft A; Madsen J; Kjaer A
Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34198666
[TBL] [Abstract][Full Text] [Related]
30. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
31. Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with
Zhang X; Tian YE; Sun F; Feng H; Yang C; Gong X; Tan G
Oncol Lett; 2015 Oct; 10(4):2253-2258. PubMed ID: 26622829
[TBL] [Abstract][Full Text] [Related]
32. Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.
Ploug M
Theranostics; 2013; 3(7):467-76. PubMed ID: 23843894
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Engelmann BE; Loft A; Kjær A; Nielsen HJ; Gerds TA; Benzon EV; Brünner N; Christensen IJ; Hansson SH; Holländer NH; Kristensen MH; Löfgren J; Markova E; Sloth C; Højgaard L
Oncologist; 2014 Feb; 19(2):164-72. PubMed ID: 24451199
[TBL] [Abstract][Full Text] [Related]
34. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.
Yang D; Severin GW; Dougherty CA; Lombardi R; Chen D; Van Dort ME; Barnhart TE; Ross BD; Mazar AP; Hong H
Oncotarget; 2016 Nov; 7(45):73912-73924. PubMed ID: 27729618
[TBL] [Abstract][Full Text] [Related]
35. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
36. Activatable Fluorescent Probes Targeting Urokinase-Type Plasminogen Activator Receptor on the Cell Membrane.
Kim TI; Cho S; Jin H; Bae J; Park C; Kim Y
Chemistry; 2023 Apr; 29(23):e202203739. PubMed ID: 36734188
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
